Focal Adhesion Kinase Inhibition Contributes to Tumor Cell Survival and Motility in Neuroblastoma Patient-Derived Xenografts

Overview

Journal Sci Rep

Specialty Science

Date 2019 Sep 15

PMID 31519958

Citations 15

Authors

Laura L Stafman

Adele P Williams

Raoud Marayati

Jamie M Aye

Hooper R Markert

Evan F Garner

Colin H Quinn

Shoeb B Lallani

Jerry E Stewart

Karina J Yoon

Kimberly Whelan

Elizabeth A Beierle

Affiliations

Soon will be listed here.

Abstract

Patient-derived xenografts (PDXs) provide an opportunity to evaluate the effects of therapies in an environment that more closely resembles the human condition than that seen with long-term passage cell lines. In the current studies, we investigated the effects of FAK inhibition on two neuroblastoma PDXs in vitro. Cells were treated with two small molecule inhibitors of FAK, PF-573,228 (PF) and 1,2,4,5-benzentetraamine tetrahydrochloride (Y15). Following FAK inhibition, cell survival and proliferation decreased significantly and cell cycle arrest was seen in both cell lines. Migration and invasion assays were used to determine the effect of FAK inhibition on cell motility, which decreased significantly in both cell lines in the presence of either inhibitor. Finally, tumor cell stemness following FAK inhibition was evaluated with extreme limiting dilution assays as well as with immunoblotting and quantitative real-time PCR for the expression of stem cell markers. FAK inhibition decreased formation of tumorspheres and resulted in a corresponding decrease in established stem cell markers. FAK inhibition decreased many characteristics of the malignant phenotype, including cancer stem cell like features in neuroblastoma PDXs, making FAK a candidate for further investigation as a potential target for neuroblastoma therapy.

Citing Articles

Novel PP2A-Activating Compounds in Neuroblastoma.

Nazam N, Bownes L, Julson J, Quinn C, Erwin M, Marayati R Cancers (Basel). 2024; 16(22).

PMID: 39594793 PMC: 11592631. DOI: 10.3390/cancers16223836.

Preclinical evidence for employing MEK inhibition in NRAS mutated pediatric gastroenteropancreatic neuroendocrine-like tumors.

Quinn C, Beierle A, Williams A, Marayati R, Bownes L, Market H Transl Oncol. 2024; 47:102045.

PMID: 38959709 PMC: 11269785. DOI: 10.1016/j.tranon.2024.102045.

Using 3D-bioprinted models to study pediatric neural crest-derived tumors.

Quinn C, Beierle A, Julson J, Erwin M, Alrefai H, Markert H Int J Bioprint. 2023; 9(4):723.

PMID: 37323483 PMC: 10261178. DOI: 10.18063/ijb.723.

Inhibition of PIM Kinases Promotes Neuroblastoma Cell Differentiation to a Neuronal Phenotype.

Julson J, Quinn C, Bownes L, Hutchins S, Stewart J, Aye J J Pediatr Surg. 2023; 58(6):1155-1163.

PMID: 36907773 PMC: 10198809. DOI: 10.1016/j.jpedsurg.2023.02.018.

A Review of the Regulatory Mechanisms of N-Myc on Cell Cycle.

Li H, Dong L, Jin M, Li Q, Wang X, Jia M Molecules. 2023; 28(3).

PMID: 36770809 PMC: 9920120. DOI: 10.3390/molecules28031141.

References

Winer J, Jung C, Shackel I, Williams P . Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem. 1999; 270(1):41-9. DOI: 10.1006/abio.1999.4085. View

Beierle E, Massoll N, Hartwich J, Kurenova E, Golubovskaya V, Cance W . Focal adhesion kinase expression in human neuroblastoma: immunohistochemical and real-time PCR analyses. Clin Cancer Res. 2008; 14(11):3299-305. DOI: 10.1158/1078-0432.CCR-07-1511. View

Stafman L, Waldrop M, Williams A, Aye J, Stewart J, Mroczek-Musulman E . The presence of PIM3 increases hepatoblastoma tumorigenesis and tumor initiating cell phenotype and is associated with decreased patient survival. J Pediatr Surg. 2019; 54(6):1206-1213. PMC: 6545248. DOI: 10.1016/j.jpedsurg.2019.02.029. View

Chen K, Huang Y, Chen J . Understanding and targeting cancer stem cells: therapeutic implications and challenges. Acta Pharmacol Sin. 2013; 34(6):732-40. PMC: 3674516. DOI: 10.1038/aps.2013.27. View

Schober M, Fuchs E . Tumor-initiating stem cells of squamous cell carcinomas and their control by TGF-β and integrin/focal adhesion kinase (FAK) signaling. Proc Natl Acad Sci U S A. 2011; 108(26):10544-9. PMC: 3127891. DOI: 10.1073/pnas.1107807108. View

Luo M, Zhao X, Chen S, Liu S, Wicha M, Guan J . Distinct FAK activities determine progenitor and mammary stem cell characteristics. Cancer Res. 2013; 73(17):5591-602. PMC: 3766468. DOI: 10.1158/0008-5472.CAN-13-1351. View

Williams A, Stewart J, Stafman L, Aye J, Mroczek-Musulman E, Ren C . Corruption of neuroblastoma patient derived xenografts with human T cell lymphoma. J Pediatr Surg. 2018; 54(10):2117-2119. PMC: 6476711. DOI: 10.1016/j.jpedsurg.2018.10.051. View

Zhao J, Reiske H, Guan J . Regulation of the cell cycle by focal adhesion kinase. J Cell Biol. 1998; 143(7):1997-2008. PMC: 2175220. DOI: 10.1083/jcb.143.7.1997. View

Beierle E, Trujillo A, Nagaram A, Kurenova E, Finch R, Ma X . N-MYC regulates focal adhesion kinase expression in human neuroblastoma. J Biol Chem. 2007; 282(17):12503-16. DOI: 10.1074/jbc.M701450200. View

10.

Gillory L, Stewart J, Megison M, Waters A, Beierle E . Focal adhesion kinase and p53 synergistically decrease neuroblastoma cell survival. J Surg Res. 2015; 196(2):339-49. PMC: 4442704. DOI: 10.1016/j.jss.2015.03.021. View

11.

Golubovskaya V, Nyberg C, Zheng M, Kweh F, Magis A, Ostrov D . A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth. J Med Chem. 2008; 51(23):7405-16. PMC: 2662449. DOI: 10.1021/jm800483v. View

12.

Weiss W, Taylor S, Shokat K . Recognizing and exploiting differences between RNAi and small-molecule inhibitors. Nat Chem Biol. 2007; 3(12):739-44. PMC: 2924165. DOI: 10.1038/nchembio1207-739. View

13.

Mitra S, Hanson D, Schlaepfer D . Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol. 2005; 6(1):56-68. DOI: 10.1038/nrm1549. View

14.

Waters A, Beierle E . The interaction between FAK, MYCN, p53 and Mdm2 in neuroblastoma. Anticancer Agents Med Chem. 2013; 14(1):46-51. DOI: 10.2174/18715206113136660331. View

15.

Cooper J, Giancotti F . Integrin Signaling in Cancer: Mechanotransduction, Stemness, Epithelial Plasticity, and Therapeutic Resistance. Cancer Cell. 2019; 35(3):347-367. PMC: 6684107. DOI: 10.1016/j.ccell.2019.01.007. View

16.

Chambers I, Tomlinson S . The transcriptional foundation of pluripotency. Development. 2009; 136(14):2311-22. PMC: 2729344. DOI: 10.1242/dev.024398. View

17.

Miller A, Garcia P, Pressey J, Beierle E, Kelly D, Crossman D . Whole exome sequencing identified sixty-five coding mutations in four neuroblastoma tumors. Sci Rep. 2017; 7(1):17787. PMC: 5736554. DOI: 10.1038/s41598-017-17162-y. View

18.

Oh L, Hafsi H, Hainaut P, Ariffin H . p53, stem cell biology and childhood blastomas. Curr Opin Oncol. 2018; 31(2):84-91. DOI: 10.1097/CCO.0000000000000504. View

19.

Owens L, Xu L, Craven R, Dent G, Weiner T, Kornberg L . Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. Cancer Res. 1995; 55(13):2752-5. View

20.

Garner E, Beierle E . Cancer Stem Cells and Their Interaction with the Tumor Microenvironment in Neuroblastoma. Cancers (Basel). 2016; 8(1). PMC: 4728452. DOI: 10.3390/cancers8010005. View